NCT02107430

Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer

Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Patients With Localized High-risk Prostate Cancer After Primary Radiotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: SOTIO a.s. · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether DCVAC/PCa added after radical primary prostatectomy can improve PSA progression times within 5 years for patients with high risk localized Prostate Cancer.

Detailed description

Treatment post radical primary prostatectomy Treatment post standard radiotherapy

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Dendritic Cells DCVAC/PCa	DCVAC/PCa arm post radiotherapy
RADIATION	Standard radiotherapy	radiotherapy

Timeline

• Start date: 2012-03-01
• Primary completion: 2013-09-01
• Completion: 2018-10-01
• First posted: 2014-04-08
• Last updated: 2018-11-14

Locations

6 sites across 1 country: Czechia